Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05046184). This is a study registration, not published results. Lead sponsor: University of Texas Southwestern Medical Center. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 104 participants (ACTUAL). Conditions: Major Depressive Disorder, Healthy Controls. Interventions: DRUG: Ketamine Hydrochloride; DRUG: Midazolam injection. Primary outcome measures: Resting State Functional Connectivity. , Baseline; Striatal Response to Frustrative Nonreward (FNR). , Baseline; Treatment-related Change in Striatum-habenula Functional Connectivity. , Assessed at baseline and end of treatment. See outcome measure 1 for baseline visit reporting; Treatment-related Change in Striatal Response to FNR. , Baseline, at 14 days. See outcome measure 2 for baseline timepoint data. Brief summary: The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs. The MDD group will also be randomized to receive ketamine or midazolam to investigate changes post-treatment in neurocircuitry with regards to irritability.